AbbVie vs Eli Lilly — CEO Pay Comparison
David Ricks (Eli Lilly) earns $3.0M more in total compensation than Robert Michael (AbbVie).
| Metric | AbbVieABBV | Eli LillyLLY |
|---|---|---|
| CEO | Robert Michael | David Ricks |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Total Compensation | $12.0M | $15.0M |
| Base Salary | $1.2M | $1.5M |
| Stock Awards | $6.0M | $7.5M |
| Option Awards | $1.4M | $1.8M |
| Non-Equity Incentive | $1.8M | $2.3M |
| Pay-for-Performance Grade | B (65/100) | A (94/100) |
| CEO-Worker Pay Ratio | 120:1 | 150:1 |
| Median Worker Pay | $100K | $100K |
| Say-on-Pay Approval | 87.2% | 87.9% |
| 3yr Total Shareholder Return | +2.5% | +66.7% |
| Revenue | $54.3B | $41.3B |
| Market Cap | $310.0B | $800.0B |
| Employees | 50,000 | 43,000 |
Analysis
Robert Michael (AbbVie) earns $12.0M in total compensation, while David Ricks (Eli Lilly) earns $15.0M. That is a difference of $3.0M.
On pay-for-performance alignment, AbbVie scores B (65/100) while Eli Lilly scores A (94/100). Eli Lilly's CEO compensation is better aligned with company performance.
AbbVie's CEO-to-worker pay ratio is 120:1 compared to Eli Lilly's 150:1. Shareholders approved CEO pay at 87.2% (AbbVie) and 87.9% (Eli Lilly).